David W Beier - Net Worth and Insider Trading

David W Beier Net Worth

The estimated net worth of David W Beier is at least $10 Million dollars as of 2025-04-11. David W Beier is the SVP, Global Govt Affairs of Amgen Inc and owns about 35,612 shares of Amgen Inc (AMGN) stock worth over $10 Million. Details can be seen in David W Beier's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that David W Beier has not made any transactions after 2012-05-03 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of David W Beier

David W Beier Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, David W Beier owns 4 companies in total, including Infinity Pharmaceuticals Inc (INFIQ) , Arcus Biosciences Inc (RCUS) , and Amgen Inc (AMGN) among others .

Click here to see the complete history of David W Beier’s form 4 insider trades.

Insider Ownership Summary of David W Beier

Ticker	Comapny	Transaction Date	Type of Owner
INFIQ	Infinity Pharmaceuticals Inc	2018-04-01	director
RCUS	Arcus Biosciences Inc	2018-03-14	director
AMGN	Amgen Inc	2012-05-03	SVP Global Govt & Corp Affairs
		2010-04-30	director

David W Beier Latest Holdings Summary

David W Beier currently owns a total of 1 stock. David W Beier owns 35,612 shares of Amgen Inc (AMGN) as of May 3, 2012, with a value of $10 Million.

Latest Holdings of David W Beier

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
AMGN	Amgen Inc	2012-05-03	35,612	279.51	9,953,910

Holding Weightings of David W Beier

David W Beier Form 4 Trading Tracker

According to the SEC Form 4 filings, David W Beier has made a total of 0 transactions in Amgen Inc (AMGN) over the past 5 years. The most-recent trade in Amgen Inc is the sale of 55,000 shares on May 3, 2012, which brought David W Beier around $4 Million.

Insider Trading History of David W Beier

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

David W Beier Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

David W Beier Ownership Network

Ownership Network List of David W Beier

No Data

Ownership Network Relation of David W Beier

David W Beier Owned Company Details

What does Infinity Pharmaceuticals Inc do?

Who are the key executives at Infinity Pharmaceuticals Inc?

David W Beier is the director of Infinity Pharmaceuticals Inc. Other key executives at Infinity Pharmaceuticals Inc include director & President & CEO Adelene Q Perkins , Chief Scientific Officer Stephane Peluso , and Chief Medical Officer Robert Jr. Ilaria .

Infinity Pharmaceuticals Inc (INFIQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Infinity Pharmaceuticals Inc (INFIQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Infinity Pharmaceuticals Inc (INFIQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Infinity Pharmaceuticals Inc (INFIQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Infinity Pharmaceuticals Inc Insider Transactions

No Available Data

What does Arcus Biosciences Inc do?

Who are the key executives at Arcus Biosciences Inc?

David W Beier is the director of Arcus Biosciences Inc. Other key executives at Arcus Biosciences Inc include director & 10 percent owner Yasunori Kaneko , director & 10 percent owner & Chief Executive Officer Terry J Rosen , and 10 percent owner Gilead Sciences Inc .

Arcus Biosciences Inc (RCUS) Insider Trades Summary

Over the past 18 months, David W Beier made no insider transaction in Arcus Biosciences Inc (RCUS). Other recent insider transactions involving Arcus Biosciences Inc (RCUS) include a net sale of 105,146 shares made by Jennifer Jarrett , a net sale of 1,840 shares made by Alexander Azoy , and a net purchase of 16,601,731 shares made by Gilead Sciences Inc .

In summary, during the past 3 months, insiders sold 0 shares of Arcus Biosciences Inc (RCUS) in total and bought 1,403,436 shares, with a net purchase of 1,403,436 shares. During the past 18 months, 142,997 shares of Arcus Biosciences Inc (RCUS) were sold and 16,641,531 shares were bought by its insiders, resulting in a net purchase of 16,498,534 shares.

Arcus Biosciences Inc (RCUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arcus Biosciences Inc Insider Transactions

No Available Data

What does Amgen Inc do?

Who are the key executives at Amgen Inc?

David W Beier is the SVP Global Govt & Corp Affairs of Amgen Inc. Other key executives at Amgen Inc include EVP & Research and Development David M Reese , EVP & Operations Esteban Santos , and SVP & Human Resources Derek Miller .

Amgen Inc (AMGN) Insider Trades Summary

Over the past 18 months, David W Beier made no insider transaction in Amgen Inc (AMGN). Other recent insider transactions involving Amgen Inc (AMGN) include a net sale of 5,802 shares made by Nancy A. Grygiel , a net sale of 35,045 shares made by Jonathan P Graham , and a net sale of 33,936 shares made by David M Reese .

In summary, during the past 3 months, insiders sold 80,076 shares of Amgen Inc (AMGN) in total and bought 0 shares, with a net sale of 80,076 shares. During the past 18 months, 94,289 shares of Amgen Inc (AMGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 94,289 shares.

Amgen Inc (AMGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Amgen Inc Insider Transactions

No Available Data

What does ARYx Therapeutics Inc do?

Who are the key executives at ARYx Therapeutics Inc?

David W Beier is the director of ARYx Therapeutics Inc. Other key executives at ARYx Therapeutics Inc include 10 percent owner Krishna Kittu Kolluri , 10 percent owner Growth Equity Opportunities Fund, Llc , and 10 percent owner Mark W Perry .

ARYx Therapeutics Inc (ARYX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ARYx Therapeutics Inc (ARYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARYx Therapeutics Inc (ARYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ARYx Therapeutics Inc (ARYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARYx Therapeutics Inc Insider Transactions

No Available Data

David W Beier Mailing Address

Above is the net worth, insider trading, and ownership report for David W Beier. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, David W Beier's mailing address is: Thousand Oaks Ca 91320-1799.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.